Michał Gniot

7PUBLICATIONS
32CO-AUTHORS
Molecular targetsGene and molecular therapyPredictive and prognostic markersHaematological tumoursPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 20, 2022
Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels.

Krzysztof Lewandowski, Zuzanna Kanduła, Michał Gniot

|Oct 14, 2022
Molecular Changes in Chronic Myeloid Leukemia During Tyrosine Kinase Inhibitors Treatment. Focus on Immunological Pathways.

Michał Janowski, Zofia Ulańczyk, Karolina Łuczkowska

|May 25, 2022
Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Helen E White, Matthew Salmon, Francesco Albano

|Dec 21, 2021
Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach.

Marzena Wojtaszewska, Rafał Stępień, Alicja Woźna

|Aug 08, 2019
Characterization and significance of the Philadelphia negative/<i>BCR-ABL1</i> positive rearrangement or masked Philadelphia translocation in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single-center study.

Blazej Ratajczak, Michal Gniot, Anna Przybylowicz-Chalecka

|Mar 07, 2018
Coexistence of JAK2 or CALR mutation is a rare but clinically important event in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

K Lewandowski, M Gniot, M Wojtaszewska

Pageof 2

Frequent Collaborators

3 joint publications

Krzysztof Lewandowski

2 joint publications

Marzena Wojtaszewska

2 joint publications

Edyta Paczkowska

1 joint publications

Tomasz Sacha